Magungunan Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararru

Yawaitar rashin lafiyar tabin hankali ya karu sosai amma bunƙasa magungunan litattafai bai ci gaba da tafiya ba, wanda ya haifar da rikici a cikin magungunan tabin hankali. Bidi'a sabon abu shine ilimin halin ɗan adam wanda ke taimaka wa ɗabi'a na ɗabi'a - amfani da MDMA, psilocybin, da LSD ta likitanci a matsayin ɓangaren haɓakar shirye-shiryen ilimin halin ɗan adam.

Wani rahoto daga ResearchAndMarkets ya ce rashin lafiyar kwakwalwa matsala ce ta gaggawa ta kiwon lafiya a duniya, musamman ma COVID-19 ya tsananta. Dangane da binciken da Harvard ya yi, an kiyasta farashin magani na yanayin lafiyar hankali zai tashi zuwa dala tiriliyan 6 nan da 2030. A cewar mai wallafa, ana sa ran kasuwar magungunan ƙwaƙwalwa za ta yi girma a cikin ƙimar 14.5% CAGR a lokacin hasashen kuma ya kai darajar dala miliyan 6330 a shekarar 2026 daga dala 3210 a shekarar 2021 saboda akwai babban buqatar jiyya da ba ta cika buqatar yin amfani da magungunan tabin hankali ba. 

Rahoton ya nuna mahimman bayanai kamar: Ketamine idanu CAGR na 16.0% tsakanin duk samfuran dangane da ƙimar kamar yadda yake da fa'ida mai ƙarfi na gwaji na asibiti a cikin cututtuka da yawa. bakin ciki (MDD, TRD), rikice-rikice-rikice-rikice-rikice-rikice-rikice-rikice, ra'ayin kashe kansa, shan kwayoyi da barasa, da damuwa na zamantakewa; Ana sa ran samfuran da ke da asalin halitta za su sami 90 BPS dangane da rabon darajar kasuwa a ƙarshen lokacin hasashen. Koyaya, samfuran roba za su kula da matsayinsu na kasuwa tare da kashi 85% na kasuwa a cikin 2026; An kiyasta baƙin cikin zai riƙe mafi girman ɓangaren ɓangaren alamun cutar tare da sama da kashi 40% na kasuwa a cikin 2021; kuma an kiyasta magungunan baka za su ba da gudummawa fiye da 55% ga kasuwar magungunan hauka ta duniya…” 

ResearchAndMarkets ya ci gaba da cewa: “Yawancin cututtukan tabin hankali sun ƙaru sosai amma haɓakar magungunan zamani ba su ci gaba da tafiya ba, suna haifar da rikici a cikin magungunan tabin hankali. Bidi'a sabon abu shine ilimin halin ɗan adam wanda ke taimaka wa ɗabi'a na ɗabi'a - amfani da MDMA, psilocybin, da LSD ta likitanci a matsayin ɓangaren haɓakar shirye-shiryen ilimin halin ɗan adam. Ana hasashen Arewacin Amurka zai kasance yanki mafi girma a cikin kasuwannin magungunan tabin hankali saboda yawan gwaji na asibiti, manyan saka hannun jari, tallafi na tsari, da wayar da kan jama'a. Nahiyar ita ce ke da rabin kudaden shiga a cikin kasuwar magungunan hauka ta duniya kuma yakamata ta kai dala miliyan $3184.0 a karshen lokacin hasashen. Ana kuma sa ran kasancewar kamfanoni masu ƙarfi da ci gaba da gwaje-gwajen asibiti za su yi kyau ga kasuwar yankin. "

Pasithea Therapeutics Ya Sanar da Shirye-shiryen Buɗe Sabbin Cibiyoyin Kiwon Lafiyar Jiki Uku a Burtaniya ta Tsakiyar 2022- Pasithea erapeutics Corp. (Pasithea" ko "Kamfanin"), wani sabon kamfani na fasahar kere-kere wanda ya mayar da hankali kan bincike da gano sabbin magunguna masu inganci don masu tabin hankali da jijiyoyin jini. rikice-rikice, a yau ta sanar da cewa, mallakarta gaba ɗaya, Pasithea Clinics, ta faɗaɗa tayin jinya kuma tana shirin buɗe sabbin asibitoci guda uku a London don kula da majinyata masu fama da matsalar tabin hankali. Kamfanin ya riga yana da wurare a Marylebone da Knightsbridge.

Asibitocin, wadanda Pasithea za su sarrafa, tare da tallafin gudanarwa daga ZEN Healthcare, ana sa ran budewa a tsakiyar 2022. Kowane asibitin zai ba da gudummawar dalar Amurka miliyan 5 a cikin kudaden shiga a shekara.

Maimaita ƙarfin maganadisu mai jujjuyawar maganadisu ("rTMS") wata dabara ce ta motsa jiki ta warkewa bisa ƙa'idar shigar da wutar lantarki. Na farko da aka haɓaka a cikin 1985, an yi nazarin rTMS a matsayin magani don ɓacin rai, psychosis, damuwa, da sauran yanayin lafiyar hankali, kuma ya nuna inganci na musamman tare da rikice-rikice masu jure wa ƙwayoyi. A cikin 2008, FDA ta amince da rTMS don amfani da shi azaman magani ga manyan bakin ciki ga marasa lafiya waɗanda ba su amsa aƙalla magungunan antidepressant guda ɗaya. Tsarin al'ada ya ƙunshi jiyya biyar a kowane mako a cikin makonni huɗu zuwa shida.